Novel agents for the management of castration-resistant prostate cancer

Current Opinion in Urology

Volumn 22, Issue 3, 2012, Pages 175-182

  Haddad, Housam ^a   Garcia, Jorge A ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

adrenal synthesis inhibition; castration resistant prostate cancer; chemotherapy and bone targeted therapy; immunotherapy

Indexed keywords

ABIRATERONE ACETATE; AMINOGLUTETHIMIDE; ANTINEOPLASTIC AGENT; CABAZITAXEL; DENOSUMAB; KETOCONAZOLE; MITOXANTRONE; PLACEBO; PREDNISONE; SATRAPLATIN; SIPULEUCEL T; TOREMIFENE; ZOLEDRONIC ACID;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; BACKACHE; BONE DENSITY; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER PREVENTION; CASTRATION RESISTANT PROSTATE CANCER; CEREBROVASCULAR ACCIDENT; DEHYDRATION; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FLU LIKE SYNDROME; HEART DISEASE; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; JAW OSTEONECROSIS; KIDNEY FAILURE; LEG EDEMA; NAUSEA; OSTEOLYSIS; OSTEOPOROSIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CASTRATION; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; LIGANDS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TREATMENT FAILURE;

EID: 84859628834     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e3283523ba0     Document Type: Review

References (50)

1. Haines AM, Larkin SE, Richardson AP, et al. A novel hybridoma antibody (PASE/4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry. Br J Cancer 1989; 60:887-892. (Pubitemid 20024181)
2. Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol 2002; 117:471-477. (Pubitemid 34226085)
3. Burch PA, Croghan GA, Gastineau DA, et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a phase 2 trial. Prostate 2004; 60:197-204. (Pubitemid 38971831)
4. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24:3089-3094. (Pubitemid 46638945)
5. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115:3670-3679.
6. Smaletz O, Scher HI, Small EJ, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002; 20:3972-3982.
7. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21:1232-1237. (Pubitemid 46606398)
8. Kantoff PW, Higano CS, Shore ND, et al., for the IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-422. The results of this clinical trial led to the FDA approval of sipuleucel-T in the USA.
9. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008; 8:440-448.
10. Taplin ME, Balk SP. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 2004; 91:483-490.
11. Navarro D, Luzardo OP, Fernandez L, et al. Transition to androgen-independence in prostate cancer. J Steroid Biochem Mol Biol 2002; 81:191-201. (Pubitemid 34879930)
12. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23:8253-8261. (Pubitemid 46211563)
13. Feldman BJ, Feldman D. The development of androgen independent prostate cancer. Nat Rev Cancer 2001; 1:34-45. (Pubitemid 33741879)
14. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 2001; 93:1687-1697. (Pubitemid 33130257)
15. Scher HI, Buchanan G, Gerald W, et al. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 2004; 11:459-476. (Pubitemid 39331277)
16. Labrie F. Adrenal androgens and intracrinology. Semin Reprod Med 2004; 22:299-309. (Pubitemid 40030080)
17. Mohler JL, Gregory CW, Ford OH, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10:440-448. (Pubitemid 38173980)
18. Harper ME, Pike A, Peeling WB, Griffiths K. Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro. J Endocrinol 1974; 60:117-125.
19. Koh E, Kanaya J, Namiki M. Adrenal steroids in human prostatic cancer cell lines. Arch Androl 2001; 46:117-125. (Pubitemid 32202486)
20. Sartor O, Cooper M, Weinberger M, et al. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of 'hormone-refractory'prostate cancer. J Natl Cancer Inst 1994; 86:222.
21. Small EJ, Baron A, Bok R. Simultaneous and antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer 1997; 80:1755.
22. Small EJBA, Fippin L, Apodaca D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 1997; 157:1204.
23. Harris KWV, Bok RA, Kakefuda M, et al. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol 2002; 168:542.
24. Figg WD, Liu Y, Arlen P, et al. A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. J Urol 2005; 173:790.
25. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004; 22:1025-1033. (Pubitemid 41095034)
26. Attard G, Reid AHM, Olmos D, de Bono JS. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 2009; 69;12:4937-4940.
27. O'Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the γ-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004; 90:2317-2325. (Pubitemid 38961894)
28. Attard G, Reid AHM, Yap TY, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26:4563-4571.
29. Reid AHM, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28:1489-1495.
30. de Bono JS, Logothetis C, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364:1995-2005. The results of this clinical trial led to the FDA approval of abiraterone acetate in the USA.
31. Tannock I, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistance prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14:1756-1764. (Pubitemid 26185452)
32. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer: results from the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17:2506-2513. (Pubitemid 29368252)
33. Harzstark AL, Rosenberg JE, Weinberg VK, et al. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the department of defense prostate cancer clinical trials consortium. Cancer 2010. doi: 10.1002/ cncr.25810. [Epub ahead of print]
34. Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009; 27:5431-5438.
35. Aller AW, Kraus LA, Bissery M-C. In vitro activity of TXD258 in chemotherapeutic resistant tumor cell lines [abstract 1923]. Proc Am Assoc Cancer Res 2000; 41:303.
36. Attard G, Greystoke A, Kaye S, de Bono J. Update on tubulin binding agents. Pathol Biol (Paris) 2006; 54:72-84.
37. Bissery M-C, Bouchard H, Riou JF, et al. Preclinical evaluation of TXD258, a new taxoid [abstract 1364]. Proc Am Assoc Cancer Res 2000; 41:214.
38. Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-h infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009; 15:723-730.
39. Pivot X, Koralewski P, Hidalgo JL, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008; 19:1547-1552.
40. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376:1147-1154. The results of this clinical trial led to the FDA approval of cabazitaxel in the USA.
41. US Department of Health and Human Services. Bone health and osteoporosis: a report of the surgeon general. Rockville, Maryland: US Department of Health and Human Services, Office of the Surgeon General; 2004.
42. Mittan D, Lee S, Miller E, et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002; 87:3656-3661. (Pubitemid 34879508)
43. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen deprivation therapy for prostate cancer. N Engl J Med 2001; 345:948-955.
44. Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352:154-164. (Pubitemid 40096612)
45. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int 2005; 16:581-589. (Pubitemid 40897454)
46. Greenspan SL, Nelson JB, Trump DL, et al. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007; 146:416-424. (Pubitemid 351650576)
47. MichaelsonMD, KaufmanDS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist induced bone loss in men with prostate cancer. J Clin Oncol 2007; 25:1038-1042. (Pubitemid 46596753)
48. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361:745-755. The results of this clinical trial led to the FDA approval of denosumab in the USA as a way to prevent bone loss in men undergoing testosterone suppression for PCa.
49. Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379:39-46.
50. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377:813-822. The results of this clinical trial led to the FDA approval of denosumab in the USA with the goal of reducing skeletal related events.